The proteins predicted to be encoded by varicella-zoster virus (VZV) genes 47 and 66 display sequence similarity to the serine/threonine family of protein kinases. Homologues ofgene 47 exist in c~-, fl-and ~-herpesviruses but homologues of gene 66 are specific to the ~-herpesviruses. Monospecific rabbit antisera were raised against two separate fusion proteins constructed from a portion of each protein fused to the carboxy terminus of fl-galactosidase. These antisera were used to characterize the 47 and 66 proteins in VZV-infected cells and in cells infected with vaccinia virus recombinants expressing each protein. The 47 protein is a 54K phosphoprotein which is distributed between the cytoplasmic and nuclear compartments of VZV-infected cells and is associated with the capsid/tegument fraction of purified VZV particles. Gene 66 encodes a 48K phosphoprotein when expressed by VZV or a vaccinia virus recombinant, and, in the latter case, the 66 protein was located exclusively in the cytoplasm. The 47 protein immunoprecipitated from VZV-infected cells could be phosphorylated in vitro, but the same protein produced by in vitro transcription and translation could not. This and other evidence indicates that additional proteins induced or encoded by VZV may be involved in the phosphorylation of the 47 protein.
Introduction
Protein kinases are involved in a wide variety of functions in eukaryotic cells, these include metabolism, cell cycle control, hormone response and control of transcription and translation. The most commonly studied eukaryotic protein kinases are those which modify serine or threonine residues (reviewed by Edelman et al., 1987) and those which modify tyrosine residues (reviewed by Hunter & Cooper, 1985) . The consensus sequence for the 240 amino acid catalytic domain of these proteins contains several highly conserved motifs (Hanks et al., 1988) , and members of the serine/threonine and tyrosine protein kinase families may be differentiated by subtle differences in these regions. The presence of such motifs, predicted from DNA sequence data, has led to the identification of a large number of putative protein kinases. Two distinct families of virus-encoded serine/ threonine protein kinase genes have been proposed in the herpesviruses, homologous to either gene US3 or gene UL13 of herpes simplex virus type 1 (HSV-1).
HSV-1 gene US3 and its counterparts in herpes simplex virus type 2 and varicella-zoster virus (VZV), genes US3 and 66 respectively, were identified as potentially encoding protein kinases by McGeoch & Davison (1986) . Smith & Smith (1989) then identified HSV-1 gene UL13, VZV gene 47 and Epstein-Barr virus (EBV) gene BGLF4 as members of a second family of putative herpesvirus protein kinase genes, and Chee et al. (1989) additionally noted a homologous gene in human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6). Neither fl-herpesviruses (e.g. HCMV and HHV-6) nor ~-herpesviruses (e.g. EBV) appear to have homologues of US3. Recent sequence data for the ~-herpesviruses pseudorabies virus (PRV) (van Zijl et al., 1990; Zhang et al., 1990; de Wind et al., 1992 ), Marek's disease virus (Ross et al., 1991) , equine herpesvirus 1 (EHV-1) (Colleet al., 1992; Telford et al., 1992) , equine herpesvirus 4 (Nagesha et al., 1993) and the 7-herpesvirus, herpesvirus saimiri (Albrecht et al., 1992) , confirm the presence of a UL13 counterpart in the ~-, fl-and ~-herpesviruses and a US3 counterpart only in the eherpesviruses.
In addition to sequence homology, there is some experimental evidence to support the notion that HSV-1 genes US3 and UL13 encode protein kinases. A monospecific rabbit antiserum directed against a predicted peptide from the US3 protein reacted with a 68K protein in extracts of cells infected with HSV-1 and with a protein of identical Mr which could be phosphorylated in vitro in highly purified fractions of the HSV-1 cytoplasmic protein kinase (Frame et al., 1987) . Deletion of the US3 gene resulted in loss of the 68K protein and the cytoplasmic protein kinase activity . In vitro phosphorylation of nuclear extracts from cells infected with HSV-1 or of disrupted HSV-1 virions yielded a 57K phosphoprotein which was identified as the UL13 protein by a monospecific rabbit antiserum directed against a UL13 fusion protein (Cunningham et al., 1992) . In experiments carried out using a mutant containing a disrupted ULI3 gene, the 57K protein was not detected by in vitro phosphorylation of nuclear or virion extracts, and a marked reduction in the phosphorylation of other HSV-1 proteins was noted (Coulter et al., 1993) .
In this paper we describe the characterization of the protein products of genes 47 and 66, the putative protein kinases of VZV, by heterologous expression and antibody techniques.
Methods

Cells and viruses.
Monolayers of CV-1 cells were grown in 5 % CO~ at 37 °C in Dulbecco's modification of Eagle's medium supplemented with 4 mM-glutamine, 100 units/ml penicillin, 100 ~tg/ml streptomycin and 5 % fetal calf serum (FCS). The VZV strain described by Dumas et al. (1981) was passaged in CV-1 cells by trypsinizing infected monolayers showing 20 to 50 % c.p.e, and adding the cells at a ratio of 1 : 5 to 1 : 1 to uninfected subconfluent monolayers. Infected monolayers were incubated in 5 % CO~ at 37 °C until 20 to 50 % c.p.e, was observed (usually 1 to 2 days), and were then used for extraction of proteins or for immunofluorescence. Vaccinia virus strain WR and recombinants derived from it were grown in CV-1 cells and proteins were extracted 16 to 20 h after infection.
Construction of plasmids.
The plasmid pDK8 was constructed for the expression of amino acid residues 95 to 322 of the VZV 66 protein fused to the carboxy terminus of fl-galactosidase. 5'-phosphorylated BamHI linkers (CGGATCCG) were ligated to a 923 bp SspI fragment obtained from a plasmid containing the VZV SstI g fragment, After digestion with BamHI and SalI, the resultant 686 bp fragment was purified and inserted into pUR289 (Rtither & M~ller-Hill, 1983) digested with BamHI and SalI.
The plasmid pDK 15 was constructed for the expression of the entire VZV 47 protein (residues 1 to 510) fused to the carboxy terminus offlgalactosidase. A 2285 bp PstI fragment obtained from a plasmid containing VZV SstI d fragment was ligated into PstI-digested pUR292 (Rtither & Mtiller-Hill, 1983) . The VZV sequence encodes residues 16 to 510 of the 47 protein. To allow expression of the entire VZV protein as a fl-galactosidase fusion, the region encoding residues 1 to 15 was reconstructed by inserting a synthetic oligonucleotide duplex between BamHI and PstI sites, so that the ATG codon of gene 47 is positioned in the context of BamHI (GGATCC), AflII (CTTAAG) and NcoI (CCATGG) sites: GGATCCTTAAGGGATCCACCATGG.
For the expression of the entire 66 protein (residues 1 to 393) from vaccinia virus, a synthetic oligonucleotide duplex comprising the first 18 codons ofgene 66 was inserted into pMJ601 (Davison & Moss, 1990) digested with Sall and NarI, such that the ATG codon is immediately preceded by a SalI site. The NarI-KpnI fragment from VZV SstI g fragment which encodes the carboxy-terminal 375 amino acids of the 66 protein and contains downstream sequences was then inserted between the NarI and KpnI sites to form pMJ702.
For expression of the entire 47 protein from vaccinia virus, a 1768 bp fragment produced by digesting pDK15 with AflII and BspMII (located downstream from ger~e 47) was cloned into pMJ601 digested with the same two restriction enzymes. This plasmid, pMJ703, was then digested with BamHI and the resultant 1768 bp fragment containing gene 47 was inserted in the required orientation into BamHI-digested pTZ 18R (Pharmacia). The resultant plasmid, pTZ47, was employed for in vitro or transient expression of the 47 protein under control of the T7 RNA polymerase promoter.
Constructiort of vaccinia virus recombinants expressing the 47 and 66
proteins. Plasmids pMJ703 and pMJ702 were used to generate vaccinia virus recombinants capable of expressing the 47 and 66 proteins at late times as described by Davison & Moss (1989) . The vaccinia virus recombinants were denoted VV47 and VV66.
Preparation of rabbit antisera directed agahtst the 47 and 66 proteins. fl-Galactosidase fusion proteins expressed in Escherichia colt containing pDK15 and pDK8 were found to be insoluble following induction by 1 mM-IPTG for 2 h at 37 °C. Consequently, the 66 fusion protein was prepared by SDS-PAGE and electroelution essentially as described by Mole & Lane (1987) . A sample of purified fusion protein was reexamined by SDS PAGE to assess recovery and the remainder was stored at -70 °C for a few days until used as immunogen.
The 47 fusion protein was partially purified by isolating insoluble inclusion bodies enriched for the 47 fusion protein by a modification of the method described by Harlow & Lane (1988) . Briefly, pelleted bacteria from a 20 ml culture were resuspended in 2 ml buffer A (50 mM-Tris-HCl pH 8-0, 1 mM-EDTA, 100 mM-NaCI) containing 1 mg/ml lysozyme, incubated for 30 min at room temperature then centrifuged at 3000 g for 10 min. The pellet was resuspended in 2 ml ice-cold buffer A containing 0.1% sodium deoxycholate and incubated at 4 °C for 10 rain. Then 16 gl of 1 M-MgCI~ and 30 ~tl of 1 mg/ml DNase I were added, and incubation was continued at 4 °C for 30 rain. After centrifugation at 600g for 10rain at 4°C, the pellet was resuspended in 1 ml 50 mM-Tris-HCl pH 8"0, 2 M-urea, recentrifuged, washed once with 1 ml buffer A and finally resuspended in 1 ml buffer A. After analysis by SDS-PAGE and assessment of protein concentration, the inclusion body preparations were stored at -20 °C and used for immunization within 1 to 2 days.
Antisera to the 66 fusion protein were prepared by Serotech. Two sandy half-lop rabbits were injected subcutaneously with 150 gg of electroeluted fusion protein in 0-5 ml PBS emulsified with an equal volume of Freund's complete adjuvant. The rabbits were boosted on days 22 and 36 with 150 gg of fusion protein in 0.5 ml PBS emulsified with an equal volume of Freund's incomplete adjuvant. Final antisera were collected on day 70.
Antisera to the 47 fusion protein were prepared by injecting two New Zealand white rabbits with 150 gg of fusion protein in an inclusion body preparation in 0.3 ml PBS emulsified with an equal volume of Freund's complete adjuvant. The rabbits were boosted on days 18, 41 and 82 with 150 gg of fusion protein from fresh inclusion body preparations in 0.3 ml PBS emulsified with an equal volume of Freund's incomplete adjuvant. Final antisera were collected on day 125.
Radiolabelling ofil~ected cells'. For labelling VZV proteins with asp, 37 mm wells in Nunc six-well multidish plates containing VZV-infected cells showing 20 to 50 % c.p.e, were rinsed twice with phosphate-free Eagle's medium lacking FCS and then incubated overnight at 37 °C with the same medium supplemented with 100 gCi/ml [32P]orthophosphate (PBS 11 ; Amersham).
For labelling recombinant vaccinia virus proteins, 37 mm wells of CV-1 cells were infected with virus at an m.o.i. 10 and incubated at 37 °C for 1 h. The infected monolayers were washed twice with phosphate-free Eagle's medium lacking FCS and incubated with the same medium supplemented with 100 laCi/ml [32P]orthophosphate at 37 °C for 16 to 20 h.
For labelling proteins expressed ,~nder the control of the T7 RNA polymerase promoter, cells were infected with a vaccinia virus recombinant expressing the T7 RNA polymerase (vTF7-3) and then transfected with plasmid pTZ47 as described by Elroy-Stein & Moss (1992) . After incubation at 37 °C for 16 h, infected cell monolayers were washed twice with Eagle's medium lacking FCS and containing 20 % of the normal amount of methionine. The monolayers were then incubated with the same medium supplemented with 100 gCi/ml [~SS]methionine (SJ 204; Amersham) for 2 to 4 h. For labelling with 3zp, infected cell monolayers were washed twice with phosphate-free Eagle's medium lacking FCS and incubated with the same medium supplemented with 100 gCi/ml [a2P]orthophosphate at 37 °C for 2 to 4h.
Immunoblotting. Infected cell monolayers from two 37 mm wells were washed twice with ice-cold PBS and then scraped into 1 ml PBS. Cells were pelleted by brief centrifugation in a benchtop microcentrifuge at 4 °C, resuspended in 0-5 ml of a 1 : 1 mixture of PBS and boiling mixture (80 mM-Tris-HC1 pH 6.8, 2% SDS, 0-1 M-DTT, 10% glycerol, 0"5 mM-bromophenol blue), heated at 100 °C for 5 to 10 rain and stored at -20 °C.
Proteins were subjected to SDS-PAGE, electroblotted onto nitrocellulose and probed with anti-47 or anti-66 sera (each at a dilution of 1:1000) using an enhanced chemiluminescence kit supplied by Amersham.
hnmunoprecipitation. Cell extracts from two 37 mm wells of radiolabelled cells were prepared in 0.5 ml lysis buffer (0.1 M-Tris-HCI pH 8.0, 10% glycerol, 0.5% NP40, 0-5% sodium deoxycholate and 0.2 mM-PMSF), and immunoprecipitation was performed as described by Murphy et al. (1989) .
Fractionation of cells.
Mock-or virus-infected cells were fractionated into cytoplasm, 0l M-, 0"4 M-and 2"0 M-NaCI nuclear wash fractions and the final 2'0 M-NaCl-resistant nuclear pellet as described by Stevenson et al. (1992) . Nuclear and cytoplasmic extracts were prepared for in vitro phosphorylation reactions as described by Coulter et al. (1993) .
Isolation of VZV particles and fractionation into capsid/tegument and envelope.
Cells from sixteen 175 cm 2 flasks of VZV-infected cells showing advanced c.p.e, were detached by shaking and collected by centrifugation at 600g for 10rain at 4°C. Virus particles were recovered from the cell pellet by a modification of the method of Dumas et al. (1980) . Briefly, the cells were resuspended gently in 2 ml of trypsin-EDTA solution (0-05 % trypsin, 002 % EDTA in PBS) and incubated at room temperature for 20 rain. Trypsinized cells were pelleted by centrifugation at 600g for 10min at 4°C and the supernatants were loaded onto 11 ml gradients of 5 to 15% Ficoll in Eagle's medium lacking phenol red. The gradients were centrifuged at 18000g for 2h at 4 °C in a Sorvall OTD-Combi ultracentrifuge using a TST41 rotor. The virus band was recovered, diluted in Eagle's medium lacking phenol red, and virus particles were pelleted at 100000g for 1 h at 4 °C and resuspended at 4 °C overnight in 100 ~1 PBS.
Resuspended virus particles were rapidly mixed with an equal volume of de-envelopment buffer (50mM-Tris HC1 pH 8.0, 0.5 MNaC1, 20 mM-EDTA, 2 % NP40) and incubated on ice for 15 min. The sample was then centrifuged for 5 rain in a benchtop microcentrifuge at 4 °C to produce a detergent-soluble membrane fraction (the supernatant) and a capsid/tegument fraction (the pellet).
Indirect immunofluorescence. Cell monolayers were fixed and permeabilized as described by Randall & Dinwoodie (1986) . Incubations with antisera and ftuorescein isothiocyanate-conjugated goat anti-rabbit antibody (Sigma) were carried out at dilutions of 1:20 and 1:80, respectively. Slides were viewed using a Nikon Microphot SA fluorescence microscope and photographed using a Nikon FX-35DX camera with Kodak Tri-X-Pan 400 film.
Preparation of acetone powders and absorption of antisera. Acetone powders of E. coli expressing fl-galactosidase or the 47 or 66 fusion proteins were prepared as described by Harlow & Lane (1988) . Briefly, 350 ml cultures of IPTG-induced E. coli were harvested and then washed with 0"9 % NaC1. Each pellet was weighed, resuspended in 0.9 % NaCI (at t mt/g wet weight), and 4 volumes of acetone at -20 °C were added. After incubation on ice for 30 min with occasional vigorous mixing, the acetone precipitate was collected by centrifugation at 600 g for 10 rain at 4 °C, resuspended in fresh acetone at -20 °C, incubated on ice for 10 min and again collected by centrifugation. The pellet was spread onto a Whatman no. 1 filter circle and dried overnight at room temperature. Powders were stored at room temperature.
Absorption of antisera against the acetone powders was performed by adding acetone powder at t % to a 1 ml volume of antiserum and incubating at 4 °C on a rotary mixer for 30 rain. After centrifugation for 5 min in a benchtop microcentrifuge at 4 °C, the supernatant was retained and the whole process was repeated a further two to five times. Absorbed sera were stored at -20 °C.
Gel electrophoresis of proteins. SDS-PAGE was conducted using 9 % polyacrylamide gels cross-linked with 1:37.5 N,N'-methylene-bisacrylamide unless otherwise indicated. Gels from immunoprecipitation experiments were incubated in fixative (10% acetic acid, 50% methanol), treated with En3Hance (New England Nuclear), dried and autoradiographed using Kodak XS-6 film with a Dupont Cronex Lightning Plus intensifying screen at -70 °C.
In vitro expression of the 47 protein. The 47 protein was expressed in vitro using a TiT-coupled reticulocyte lysate system (Promega). Plasmid pTZ47 was used as template for T7 RNA polymerase and proteins were labelled with [3~S]methionine according to the manufacturer's protocol.
In vitro phosphorvlation of proteins. In vitro phosphorylation reactions were carried out using crude nuclear or cytoplasmic extracts or immunoprecipitated proteins. Volumes of 10 gl of extracts or 20 B1 of packed Protein A-Sepharose beads used in immunoprecipitations were mixed with an equal volume of assay mixture containing 50 mMTris HCI pH 7-5, 1 mM-DTT, 1 gCi [y-aZP]ATP and either 0-1 M-or 1.5M-NaCI in the presence of 10mM-MgC12 or 10mM-MnCI 2. Reactions were incubated for 30 min at 37 °C and terminated by addition of an equal volume of SDS-PAGE boiling mixture. Samples were heated at 100 °C for 5 min and analysed by SDS-PAGE.
Results
The products of VZV genes 47 and 66 in VZV-blfected cells Fig. 1 b, lane 1) . The Fig. 2 shows the result of an immunoprecipitation experiment using serum from a rabbit immunized with a /~-galactosidase fusion protein containing residues 95 to 322 of the 66 protein (anti-66 serum). Two major phosphoprotein species with apparent Mrs of 48K and 54K were precipitated by immune serum from a~p_ labelled extracts of VZV-infected cells (lane 4) but not from extracts of mock-infected cells (lane 3). These proteins were immunoprecipitated in variable relative proportions in different experiments, but neither was precipitated by the preimmune serum (lanes 1 and 2). In contrast to the anti-47 serum, the anti-66 serum did not react convincingly with immunoblots of extracts from VZV-infected cells (data not shown), but did react with extracts of cells infected with VV66 (as described below). This may indicate that a relatively low level of target antigen is present in VZV-infected cells.
Expression of the 47 and 66 proteins by recombinant vaccinia viruses
Expression of the 47 and 66 proteins by recombinant vaccinia viruses, VV47 and VV66, was assessed by immunoblotting and immunoprecipitation experiments. Transient expression of the 47 protein was also achieved by transfection of pTZ47 into cells infected with vTF7-3, a vaccinia virus recombinant which expresses T4 R N A polymerase. Fig. 3(a) shows that the anti-47 serum reacted in an immunoblot experiment with a 54K protein which was present in extracts of cells infected with VV47 (lane 1) but not in extracts of cells infected with a vaccinia virus recombinant expressing a portion of VZV gene 61 (lane 2). This protein was not detected by immunoprecipitation of asS-or a2P-labelled extracts of VV47-infected cells (data not shown). The 54K protein was immunoprecipitated from extracts of a~S-labelled cells transfected with pTZ47 after infection by vTF7-3 (Fig. 3b, lane 1 labelled with 32p (Fig. 3b, lane 2) . These results imply that the 47 protein is present at low levels in VV47-infected cells (as indeed m a y be the case in VZV-infected cells) and that p h o s p h o r y l a t i o n of the 47 protein is reduced when it is expressed in isolation from other proteins induced or encoded by VZV. (Fig. 4 b) also showed recognition of a 48K protein in extracts of VV66-infected Fig. 6 (a) indicates that the 47 protein was found in both the cytoplasmic and nuclear fractions of VZV-infected cells, with part o f the latter being resistant to elution by 2"0 M-NaC1. As indicated above, the anti-66 serum did not react convincingly in i m m u n o b l o t t i n g experiments with VZV-infected cell extracts, b u t did react with extracts of cells infected with VV66 (e.g. see Fig. 4a ). W h e n VV66-infected cells were analysed, the 66 protein was located exclusively in the c y t o p l a s m (Fig. 6 b) . serum (Fig. 7 c) and anti-47 serum absorbed against flgalactosidase (Fig. 7d) or the 66 fusion protein (Fig. 7e) showed association of the 47 protein with large nuclear inclusions in VZV-infected cells. Similar immunofluorescence was not detected in mock-infected cells probed with anti-47 serum (Fig. 7b ) or in VZV-infected cells probed with pre-immune serum (Fig. 7a) or with anti-47 serum absorbed against the 47 fusion protein (Fig. 7f) . It was not possible to confirm from these results that the majority of the 47 protein was cytoplasmic (as was inferred from subcellular fractionation of VZV-infected cells), since mock-infected cells exhibited non-specific cytoplasmic fluorescence when probed with anti-47 serum (Fig. 7 b) . Nevertheless, the lack of nuclear fluorescence observed when VZV-infected cells were probed with anti-47 serum absorbed against the 47 fusion protein (Fig, 7f) confirmed that the nuclear fluorescence was specific to the 47 protein.
Confirmation of the identity of the 66 protein
Subcellular localization o f the 47 and 66 proteins
Mock-infected cells also exhibited non-specific cytoplasmic fluorescence when probed with anti-66 serum (result not shown). Consequently, this serum proved to be of little use in immunofluorescence experiments and the cytoplasmic localization of the 66 protein indicated by irnmunoblotting experiments could not be confirmed by this method.
Association of the 47 prote#7 with virus particles
Virus particles removed from infected cells by trypsin treatment were separated into capsid/tegument and envelope fractions, and samples were analysed by immunoblotting (Fig. 8) . The 47 protein was found to be associated with VZV-infected cells and virus particles (lanes 2 and 3), and reaction with virus particles from which the envelopes had been removed indicated a likely association with the capsid/tegument fraction (lane 4). Removal of the viral envelope was confirmed by immunoblotting parallel fractions with monoclonal antibodies directed against the envelope gtycoproteins gpI, -II and -III (data not shown). 
Discussion
Monospecific antisera were used in an i m m u n o l o g i c a l analysis of the two putative protein kinases o f VZV, the products of genes 47 and 66. The 47 and 66 proteins have a p p a r e n t Mrs of 54K and 48K respectively, similar to their predicted Mrs of 54K and 44K (Davison & Scott, 1986 Ng & Grose (1992) that the 47 protein is a 54K phosphoprotein in VZV-infected cells and that it is distributed largely in the cytoplasm (as assessed by indirect immunofluorescence). We have confirmed, by fractionation of VZV-infected cells, that the major fraction of the 47 protein is cytoplasmic, but have also demonstrated by two independent methods that a proportion is associated with the nuclei of infected cells. This difference may be due to the alternative methods of fixation and permeabilization used in immunofluorescence. Our result is consistent with the presence of the 47 protein in the capsid/ tegument fraction of VZV particles purified from the surfaces of infected cells.
The targets of the HSV-I UL13 and US3 protein kinases have been reported to be the US1 and UL34 proteins (Purves et al., 1991 , respectively. The site of phosphorylation of the UL34 protein was initially proposed on the basis of studies of in vitro phosphorylation of synthetic peptides by the US3 protein kinase (Purves et al., 1986) , and has been investigated by mutagenesis of the UL34 protein (Purves et al., 1991) . Comparable sites are not present in the homologous VZV (Davison & Scott, 1986) or EHV-1 proteins (Telford et al., 1992) . It is possible that the US3 protein kinases of VZV and EHV-1 have different targets from that of the HSV-1 US3 protein kinase. More probably, the family of US3 protein kinases may have a common unidentified target but also have additional targets specific to each virus (e.g. the UL34 protein of HSV-1) which may or may not be of biological significance. Similar comments apply to the UL13 protein kinase family, which has members in all herpesvirus subfamilies but whose reported target in HSV-1 has counterparts only in 0~-herpesviruses.
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